The cardiac safety during treatment with sunitinib and sorafenib, multikinase angiogenesis inhibitors
Journal Title: OncoReview - Year 2012, Vol 2, Issue 2
Abstract
Cardiotoxicity of multikinase angiogenesis inhibitors, sunitinib and sorafenib, is most often myocardial systolic dysfunction or arterial and venous thromboembolic events. Essential risk factor seems to be iatrogenic arterial hypertension, which is a typical (“class effect”) vascular complication and a predictive factor of the anticancer efficiency. A biochemical and molecular aspect is associated with cardiomyocytes damage and endothelial dysfunction. Specific primary cardioprotective options are still unknown. It was shown the real risk of cardiotoxicity of multikinase angiogenesis inhibitors, sunitinib and sorafenib, in relation to the risk of cardiotoxicity of bevacizumab, the monoclonal antibody anti-VEGF.
Authors and Affiliations
Sebastian Szmit
Keywords
Related Articles
- EP ID EP53161
- DOI -
- Views 256
- Downloads 0
Cukrzyca posterydowa w onkologii – zasady diagnostyki i leczenia
Jedną z grup, w której należy spodziewać się wystąpienia cukrzycy w wyniku podawania glikokortykosteroidów, są chorzy na choroby nowotworowe. Zasady rozpoznania tej formy cukrzycy nie różnią się od zasad rozpoznania inny...
Administration of liposomal doxorubicin in patients with metastatic breast cancer and significant concomitant cardiovascular conditions
A frequent dilemma faced by an oncologist about to take decision on a chemotherapeutic regime for patients with metastatic breast cancer is how to maintain balance between the expected treatment efficacy and predictable...
Multiple myeloma. Practical aspects regarding diagnosis and treatment
Practical aspects of multiple myeloma diagnosis and treatment has been discussed. Myeloma diagnosis should be supported with immunoglobulin’s isotype and serum free light chain immunoglobulins studies. It is particularly...
Bone marrow transplantation – how can we maximize cardiac status?
Improving cancer outcomes through better cancer data in Poland
Based on NFZ published aggregate data, the public spending on cancer care in Poland was 6.3 billion PLN in 2011 (or approximately 10% of total public health spending). Poland is one of the few large countries in the worl...